ArticleResearch square2025
V-synthes2 - the Next Generation Tool for Structure-based Virtual Screening of Giga-scale Chemical Spaces.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
Abstract
The recent advent of synthesizable on-demand chemical spaces of drug-like compounds opened new horizons in the discovery of ligands and drug candidates for clinically relevant targets, but exposed the scalability of computational screening as a key bottleneck. The modular V-SYNTHES approach has shown highly efficient > 1000-fold accelerated virtual screening, but its initial implementation was not fully automated, limited to the initial version of Enamine REAL space (11 billion), and its validation was limited to only two targets. Here we present an upgraded V-SYNTHES2 workflow with improved automation features and scalability, expanded REAL Space of 36 billion readily available compounds, and assessing its performance on new, more challenging targets. As the original method, V-SYNTHES2 employs initial docking of the Minimal Enumeration Library (MEL) of fragments that represent all scaffolds and synthons of the REAL space. The best fragments are iteratively enumerated with corresponding synthons, and the intermediates redocked, until the fully enumerated molecules are docked and selected for synthesis. V-SYNTHES2 introduces a new geometry-based CapSelect method, allowing us to fully automate MEL fragment selection based on docking score and optimal binding pose. The method shows excellent enrichment and binding pose reproducibility in computational benchmarks, including challenging targets with shallow pockets, RNA-binding sites, G-protein-coupled receptors (GPCRs), and phospholipid-binding enzymes. Experimental testing shows the utility of this workflow in prospective screening campaigns for two new targets. The fully automated V-SYNTHES2 workflow (https://github.com/KatritchLab/V-SYNTHES2_pipeline/) can be deployed on computing clusters or clouds, offering a powerful tool for effective screening of giga-scale chemical spaces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.